Deadly Ebola virus outbreak in Uganda, 2022: An imminent threat to the public health and safety

Naeem, Aroma; Zaheer, Zaofashan; Kalsoom, Tuaseen; Tabassum, Shehroze; Albakri, Khaled; Wireko, Andrew A

doi:10.1097/ms9.0000000000000216

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following coordinated efforts by regional health authorities, the World Health Organization (WHO), and other partners, the outbreak was deemed to be under control in June 2020. According to a WHO announcement, the current Ebola epidemic in Uganda was formally declared on September 20, 2022, following the discovery of a case of the Sudan virus disease in the central Ugandan region of Mubende [40].…”

Section: Discussionmentioning

confidence: 99%

The Tactical Strategy, Readiness, Epidemiology and Reaction to Potential Treatments for the Possibly Lethal Ebola Virus: A Review

Fatima,

Panwar,

Varnika

et al. 2024

UPJOZ

View full text Add to dashboard Cite

Over the preceding 38 years, a few outbreaks have been brought on by the Ebola virus, which produces the Ebola illness. No specific treatment has been approved for EVD. Problem management and supportive care are the cornerstones of treatment. Effective outbreak control requires a multidisciplinary team effort that includes case care, infection prevention and control protocols, contact tracing and surveillance, a high-quality laboratory service, dignified and safe funerals, and social and community mobilization. The 2014 Ebola outbreak started in Africa and swiftly spread to other continents before turning into a pandemic. The illness gained international interest because to its relatively peculiar design, lethality and contagiousness, difficulty in containing its spread, and absence of a reliable treatment. Two medications have received FDA approval to treat EVD. Ebanga is a single monoclonal antibody, whereas Inmazeb is a mixture of three monoclonal antibodies. Individuals utilizing any of the two FDA-approved treatments had a significantly greater overall survival rate. In this article, the known history of the Ebola virus, its mode of infection, epidemiology, lifecycle, and possible treatments are briefly reviewed.

show abstract

Section: Discussionmentioning

confidence: 99%

The Tactical Strategy, Readiness, Epidemiology and Reaction to Potential Treatments for the Possibly Lethal Ebola Virus: A Review

Fatima,

Panwar,

Varnika

et al. 2024

UPJOZ

View full text Add to dashboard Cite

show abstract

“…The virulent nature of EVD and the speed at which it kills is well-documented (31,32). The EVD incubation period stands at 2 to 21 days with an acute onset without any carrier status (33) with a typical fatality rate of almost 50% ranging from 25 to 90% (34). Evidence further indicates that the perceived threat of illness has higher chance of prompting positive actions toward its prevention and management (35).…”

Section: Discussionmentioning

confidence: 99%

Community Perspectives of Ebola Viral Disease in High-Risk Transmission Border Regions of Tanzania: A Qualitative Inquiry

Metta,

Mohamed,

Kusena

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Tanzania faces ever-rising concerns due to the recurrence of the Ebola Virus Disease (EVD) in neighboring Democratic Republic of Congo (DRC) and Uganda. This necessitates a better understanding of the community perspectives in high-risk regions for effective risk communication and preparedness. Methods: This rapid ethnographic assessment study used explorative qualitative methods to collect data. People from diverse backgrounds participated in 59 in-depth interviews, 57 Key Informant interviews, and 35 focus group discussions. Data was analysed using a thematic analysis approach. Findings: The study found high awareness of EVD and its symptoms, with radio and television emerging as the primary source of information. However, participants had mixed perceptions of EVD’s cause and transmission, with some believing that bats, monkeys, and wild animal meat caused it. In contrast, others associated the disease with high fever, a dirty environment, changing dietary patterns, and the COVID-19 virus. Physical contact with an infected person, eating cascades of infected wild animals, and contact with an infected person’s fluids were perceived as EVD transmission agents. Due to their daily activities, women, school children, boda-boda riders, and fishermen were perceived as the most susceptible to EVD infection. Preventive measures included avoiding physical contact, touching fluids, and refraining from eating wild animal meat. Prompt reporting of suspected cases to health facilities was reported as crucial for earlier outbreak identification and containment. Conclusion: The high-risk regions of Tanzania had a high level of awareness and perceived susceptibility to EVD, coupled with varying degrees of misperception about the etiology and its transmission. To improve community perspectives and preparedness in the case of an outbreak, there is a need for ongoing risk communication and involvement in EVD prevention and responses.

show abstract

In-silico identification of novel natural drug leads against the Ebola virus VP40 protein: A promising approach for developing new antiviral therapeutics

Siddiquee,

Hossain,

Talukder

et al. 2024

Informatics in Medicine Unlocked

View full text Add to dashboard Cite

Deadly Ebola virus outbreak in Uganda, 2022: An imminent threat to the public health and safety

Cited by 4 publications

References 7 publications

The Tactical Strategy, Readiness, Epidemiology and Reaction to Potential Treatments for the Possibly Lethal Ebola Virus: A Review

The Tactical Strategy, Readiness, Epidemiology and Reaction to Potential Treatments for the Possibly Lethal Ebola Virus: A Review

Community Perspectives of Ebola Viral Disease in High-Risk Transmission Border Regions of Tanzania: A Qualitative Inquiry

In-silico identification of novel natural drug leads against the Ebola virus VP40 protein: A promising approach for developing new antiviral therapeutics

Contact Info

Product

Resources

About